Innoviva Inc Revenue Growth Rates (INVA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Innoviva Inc   (NASDAQ: INVA)
 

INVA's Revenue Growth by Quarter and Year

Innoviva Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INVA/growth
https://api.csimarket.com/api/v1/companies/INVA/fundamentals
https://api.csimarket.com/api/v1/companies/INVA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
INVA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 106.12
2nd Quarter June 119.59
1st Quarter March 90.83
FY 316.54

INVAs Annual Revenue
Innoviva Inc 's Revenue in the fiscal year 2025 $ 384.67 millions
Innoviva Inc 's Revenue in the fiscal year 2024 $ 417.87 millions
Innoviva Inc 's Revenue in the fiscal year 2023 $ 310.46 millions
Innoviva Inc 's Revenue in the fiscal year 2022 $ 322.88 millions
Innoviva Inc 's Revenue in the fiscal year 2021 $ 391.87 millions




INVA Revenue third quarter 2026 Y/Y Growth Comment
Innoviva Inc reported Revenue growth of 5.55% year on year in the third quarter 2026, to $ 106.12 millions, this is lower than Innoviva Inc 's recent average Revenue rise of 76.78%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue growth. While Innoviva Inc ' s Revenue increase of 5.55% ranks overall at the positon no. 3155 in the third quarter 2026.


INVA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.55 %
2nd Quarter June 28.38 %
1st Quarter March 11.69 %
FY   -

Financial Statements
Innoviva Inc 's third quarter 2026 Revenue $ 106.12 millions INVA's Income Statement
Innoviva Inc 's third quarter 2025 Revenue $ 100.54 millions Quarterly INVA's Income Statement


INVA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -11.26 %
2nd Quarter June 31.66 %
1st Quarter March -17.18 %
FY (Year on Year)   -


Back to INVA Growth rate Comparisons >> Back to INVA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #425
Overall #3155

Revenue Y/Y Growth Statistics
High Average Low
975.13 % 76.78 % -96.64 %
(Sep 30 2015)   (Dec 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #425
Overall #3155
Revenue Y/Y Growth Statistics
High Average Low
975.13 % 76.78 % -96.64 %
(Sep 30 2015)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Innoviva Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2270.81 % 65.04 % -98.87 %
(Mar 31 2012)  


INVA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Innoviva Inc disclosed drop in Revenue from the second quarter by -11.26% to $ 106.12 millions, from $ 119.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Innoviva Inc 's Revenue growth quarter on quarter, overall rank is 352.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #352
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #352
Revenue Q/Q Growth Statistics
High Average Low
2270.81 % 65.04 % -98.87 %
(Mar 31 2012)  


INVA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Innoviva Inc disclosed drop in Revenue from the second quarter by -11.26% to $ 106.12 millions, from $ 119.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Innoviva Inc 's Revenue growth quarter on quarter, overall rank is 352.


Innoviva Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 420.63
Y / Y Revenue Growth (TTM) 13.36 %
Year on Year Revenue Growth Overall Ranking # 2759
Seqeuential Revenue Change (TTM) 6.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 3185


Cumulative Revenue growth Comment
Although Innoviva Inc 's Annual Revenue growth year on year were below company's average 76.78% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.36% year on year, from -3.47% in Mar 31 2026.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 339 to 2759.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 391
Overall # 2759

Revenue TTM Y/Y Growth Statistics
High Average Low
975.13 %
 76.78 %
-96.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 426
S&P 500 # 3185
Cumulative Revenue growth Comment
Although Innoviva Inc 's Annual Revenue growth year on year were below company's average 76.78% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.36% year on year, from -3.47% in Mar 31 2026.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 339 to 2759.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 391
Overall # 2759

Revenue TTM Y/Y Growth Statistics
High Average Low
975.13 %
76.78 %
-96.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 426
S&P 500 # 3185




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INVA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions
Haemonetics Corporation9.49%$ 9.492 millions
Progyny Inc 9.08%$ 9.084 millions
Ironwood Pharmaceuticals inc 9.00%$ 8.996 millions
Encompass Health Corporation8.93%$ 8.934 millions
West Pharmaceutical Services Inc 8.73%$ 8.728 millions
Resmed Inc 8.67%$ 8.667 millions
Carlisle Companies Incorporated8.65%$ 8.649 millions
Concentra Group Holdings Parent Inc 8.61%$ 8.611 millions
Merit Medical Systems Inc8.56%$ 8.563 millions
Medpace Holdings Inc 8.50%$ 8.501 millions
Pulmonx Corporation8.47%$ 8.470 millions
Amgen Inc 8.45%$ 8.455 millions
Precipio inc 8.33%$ 8.335 millions
Fulgent Genetics Inc 8.26%$ 8.262 millions
Amphastar Pharmaceuticals Inc 8.22%$ 8.219 millions
Ultragenyx Pharmaceutical Inc 8.17%$ 8.170 millions
Baxter International Inc 8.08%$ 8.078 millions
Tactile Systems Technology Inc 8.07%$ 8.067 millions
Iqvia Holdings Inc 8.00%$ 8.000 millions
Exagen Inc 7.86%$ 7.859 millions
Gyre Therapeutics Inc 7.75%$ 7.754 millions
Stryker Corp7.64%$ 7.644 millions
Bausch and Lomb Corp7.34%$ 7.338 millions
Addus Homecare Corp7.19%$ 7.193 millions
Pacific Biosciences Of California Inc 7.03%$ 7.026 millions
Bristol myers Squibb Company6.93%$ 6.930 millions
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions


About Innoviva Inc Revenue Growth Rates (INVA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Innoviva Inc (CIK 1080014).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-447384
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Innoviva Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.